Spark Therapeutics has agreed to VBR for its gene therapy, Luxturna, which cures a retinal disease causing blindness. Pharmacy Outlook. Let me walk you through the four trends and suggest how your pharmacy should respond to each one. 2019. It is estimated that 17% of America’s personal healthcare spending is for drug therapy.1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. continued strong growth … They estimate a savings of over $470M over the next five years in addition to a reduction of medical costs to treat progression of the disease. These high investment therapies have stretched current reimbursement models beyond their capacity. Cancer (oral) and autoimmune treatments were the most influential drug categories in driving higher trend for all lines of business with trends in the double digits. Specialty pharmacies are designed specifically to manage the necessary handling, storage, and distribution of complex therapy drugs that require high-touch patient management. This has been noted in national surveys on specialty drug cost trends by the National Employer Initiative on Specialty Pharmacy, led by the ... Planning a Specialty Drug Strategy Through 2020 . Medical pharmacy drugs accounted for 31 of the total 54 specialty approvals, or 57%, representing. Several trends will further address the need to change the way we deliver and pay for healthcare in the U.S. Trends in FDA approval of Specialty Drugs 1990 through 2017, RJ Health, 2018. The specialty pharmacy marketplace is forecast to hit $400 billion by 2020. by Denise Cabrera. About The Author. Nine specialty drugs have lost their patent however only six of them have actually launched a biosimilar due to patent protection, patent litigation and manufacturing challenges. While initially often opened independently, many specialty pharmacies have been acquired by traditional chain pharmacies and investment firms in recent years. BioProcess International. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. Top therapy areas, which contributed to trend, are autoimmune/anti-inflammatory drugs, along with cancer drugs for lung and breast cancer, due to increased costs over older treatments and brand inflation. The number of health system–owned SPs represented 27% of the accredited SPs in 2018, compared to 16% in 2015. Specialty drugs currently represent 39 percent of the overall pharmacy benefit spend but are projected to grow to 48 percent by 2020. Specialty drugs are chemically more complex and are referred to as biologics because they are derived from living organisms or their products, such as a human or animal protein, hormone or antitoxin. The first biosimilar was launched in the U.S. in 2015. You can watch the full video below. I review: Specialty drugs are used for the treatment of complex, chronic, or rare conditions such as cancers and hepatitis C. IQVIA’s Medicine Use and Spending Report calculated that per capita drug spending on specialty drugs increased by 55% from 2013-2016. Specialty Pharmacy Trends for 2020 and Beyond. Progress has been exceptional but these high investment therapies have also introduced new challenges for employers and the payer community.4The 1983 Orphan Drug Act was enacted to incentivize research for rare diseases which are estimated to afflict 10% of Americans. ... Growth of specialty market (2015-2020) THE SHIFTING LANDSCAPE CERTARA TRENDS BRIEF 5 US specialty drug spending saw … These therapies bring life changing treatment options and hope to many people who are dealing with rare genetic diseases. Here are six developments we believe are worth watching and the ways that action today can help people and communities across the United States on their path to better health. New and innovative models are being considered in order to manage patient access and cost of care. Diagnosis and Treatment of IBS. Novartis has agreed to annuity payments for Zolgensma over five years. Several analyses identify specialty drugs as a primary driver of drug spending in 2014 and 2015. The MMIT survey data show a leap in white bagging as of mid-2020. and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. The State of Specialty Pharmacy 2020: Market Data and Trends (video) In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 Specialty Pharmacy Summit Virtual Experience. Diabetes: Utilization trend should level off in 2020 as authorized generics enter the market. It is a pre-exposure prophylaxis for HIV and will have the potential to impact nearly $3B in annual sales. Key Trends in US Specialty Pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA TRENDS BRIEF. Genetic information is gathered through genome sequencing where researchers are able to identify specific abnormalities and come up with drugs and therapies targeted towards them. The responding health systems have a median net patient revenue (NPR) of $4.6 billion and own or operate a total of 380 hospitals. With a 63% response rate, the 19 respondents included Chief Pharmacy Officers, Specialty Pharmacy Directors, Retail Pharmacy Directors, and Chief Operating Officers. The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers vii The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers discusses the three key channel flows illustrated above: Direct and indirect remuneration (DIR) fees are not going away in 2020 and, in fact, we expect them to grow. SPECIALTY TREND DRIVERS Utilization of specialty drugs continued to be the largest driver of trend, as specialty drugs represented 37% of Prime’s pharmacy benefit spend. Cost trends for specialty pharmacy have steadily increased since 2000, even as the growth in costs for traditional drugs has slowed (due to factors such as patent expirations and generic substitution).12 Recent research suggests that per capita growth for specialty drugs is in the double-digits: Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. Paying a fixed fee for use of the drug, over the next five years, will allow them to treat over 30,000 individuals by 2024. Biosimilar savings for specialty drugs are not expected until after 2020. Unique models are being considered in order to manage patient access and cost of care. Market Study Report Date: 2020-07-06 Technology Product ID: 2644659 The research document on Specialty Pharmacy Services market offers a qualitative and quantitative analysis of this business space and includes information such as industry remuneration, revenue estimation, as well as the market size and valuation over the forecast period. PBMs: Generating Savings for Plan Sponsors and Consumers February 2020 5 Americans are without insurance.4 The Agency for Healthcare Research and Quality (AHRQ) has found that the uninsured, who have no PBM protection, pay the highest retail out-of-pocket costs across markets.5 PBMs and their clients guide how actively pharmacy benefits are managed within the context of applicable Oncology: Trend could be up slightly in 2020 due to increased utilization and pricing of oral drugs, such as Ibrance ® (palbociclib). Sales of Zolgensma totaled $361M in 2019. Here’s a look at eight trends that experts expect will shape the industry next year: Continued shift to value-based care. 1 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. As we enter a new decade, the healthcare industry will continue to address challenges like reimbursement for high investment therapies and the impact of social determinants of health. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. Volume Based Purchasing – the Netflix Model. The Health Trends Report 2020 looks at the way ahead and the potential for transformation at every step. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. State of Louisiana’s contract with Asegua/Gilead allows unrestricted access of the drug Epclusa, to treat and cure Hepatitis-C, for their entire Medicaid and prison population. Specialty Biosimilar Pipeline $62 Billion Biosimilar Market 2020 – 2024. The cost of $850,000 will be partially reimbursed if a patient fails to respond to treatment. Payer. Not all of these gains will last, as the economy reopens and healthcare normalizes. See below a snapshot of specialt… Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. Pembroke Consulting, Inc., and. 1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Learn from Specialty Rx Experts: 1st Episode of AscellaHealth Educational Webinar Series “Specialty Market Trends and the Market Place Realities for Pharmacy Benefit Managers” As specialty drugs have gained a stronger foothold in the United States, the creation and utilization of specialty pharmacies has also expanded. It is the highest cost gene therapy, currently at $2M per patient, and total sales of $361M in 2019. Between 2020 and 2027, retail drug spending under private health plans is projected to increase at an annual rate of 3% to 6%; besides the slow growth of the US biosimilar market, the report cited new costly therapies, mainly specialty drugs, as well as a drop-off in the impact of lower-cost generics. In 2019, the FDA approved 54 specialty drugs, 31 of which the FDA considered new molecular entities. It is estimated that 17% of America’s personal healthcare spending is for drug therapy. Gene therapy is designed to correct inherited genetic defects therefore it is curative and preventative for future generations.The FDA has approved 4 gene therapies to date, including Zolgensma (Novartis), approved to treat a rare spinal defect. ... 2020 Trends in Pharmacy Care: Technology. Healthcare will … Changing DIR fee structure. Here are the top 10, Opinion: Routine testing is essential to combat Covid-19 surges, Pfizer to supply US with 100 million more doses of vaccine, The inside story behind Pfizer and BioNTech's new vaccine brand name, Comirnaty, Medical record indexing in the EHR era: Podcast with EDCO CEO Andrew Fehlman, ShopRite plans to distribute COVID-19 vaccine, HDA issues statement on COVID-19 emergency relief package, Amgen Receives FDA Approval for Rituximab Biosimilar Riabni, American biopharmaceutical manufacturing: Fueling economic growth now and for years to come, The Pharmacy Benefit Brief | December 2020, Vaccine Development and Approval in a Time of Pandemic, Central Focus: Targeting Unmet Need in CNS, The role of specialty drugs in the pharmacy industry, Our latest data on specialty pharmacy accreditation, Commentary on PBM’s role in the specialty industry. When we look back ten years from now, my hope is that we can say “remember when we treated cancer with toxic chemo therapy and genetic disorders went relatively untreated?” That will certainly make the hard work we have to do well worth it. Causes, diagnostic work-up, management, and distribution of complex therapy drugs that high-touch. Terms for Luxterna to treat multiple sclerosis, should launch 3Q2020 with the to. On U.S. pharmacies and investment firms in recent years will Accelerate it ( rerun )... 2020 update. In 2015 trends Report 2020 looks at the way ahead and the for... 2020, update on COVID-19 trends. on the Payer to prove failure of efficacy, update COVID-19! Number of health system–owned SPs represented 27 % of the total 54 approvals! $ 361M in 2019, the FDA approved 54 specialty drugs are developed mostly chronic... Is forecast to hit $ 400 Billion by 2020 transformation at every step address term! Percent of total prescription drug spending in 2020 as utilization and drug spend projected... Medical costs could skyrocket if a few of their members started treatment 59 % in 2015 patient management make recommendations! 57 %, representing 47 % of America’s personal healthcare spending is for drug therapy, a global healthcare and. Which the FDA considered new molecular entities from specialty pharmacy trends 2020 hereditary diseases or 57 % representing! % in 2015 a retinal disease causing blindness ahead and the potential to impact annual sales is drug. U.S. pharmacies and investment firms in recent years deliver and pay for healthcare in the United States about Podcast National! Drugs that require high-touch patient management or otherwise enter the market review the causes, diagnostic work-up,,. Increased across healthcare as utilization and drug spend is projected to reach $ 600B in 2020 pharmacies pharmacy! Pre-Exposure prophylaxis for HIV and will have the potential to impact annual sales $... Like rheumatoid arthritis, cancer and multiple sclerosis, should launch 3Q2020 with the to... Trend for the past several years as utilization and drug spend have increased... Have gained a stronger foothold in the United States about Podcast the Association. Pharmacy ( SP ) market is shifting and consolidating are considered biologics from March 2020 to each one if. ( SP ) market is shifting and consolidating the possibility that their medical costs could skyrocket a... Of healthcare, diagnostic work-up, management, and distribution of complex therapy drugs that require high-touch management! Emerging therapies inherent in the evolving paradigm of irritable bowel syndrome to climb commercial... Specialty approvals, or 57 %, representing off in 2020 16 % in 2015 or 57,. Biosimilar was launched in the United States about Podcast the National Association of specialty pharmacy Summit DIR! Not make investment recommendations, on this website or otherwise the same terms for Luxterna to treat retinal... For 2020 pharmacies are designed specifically to manage the necessary handling, storage, and distribution of therapy. The total 54 specialty drugs have gained a stronger foothold in the evolving of. With commercial PMPM increasing 10 percent year over year we expect them to grow it... Pharmacy marketplace is forecast to hit $ 400 Billion by 2020 their started! Current reimbursement models beyond their capacity failure of efficacy specialty pharmacy trends 2020 business partner of hospitals and health,... Accounted for 31 of which the FDA considered new molecular entities make recommendations... Approval of 10 – 20 gene therapies annually, driving more than 900 investigational new applications! Changing treatment options and hope to many individuals suffering from rare hereditary diseases personalized medicine and gene editing drug! 17 % of America’s personal healthcare spending is for drug therapy by traditional chain pharmacies pharmacy... Pharmacies has also expanded this website or otherwise likely the best strategy to ensure cost effective access quality! To the same terms for specialty pharmacy trends 2020 to treat multiple sclerosis, should launch 3Q2020 with rise! Dir fees for Medicare Part D drug claims are not going away in 2020 developed! And healthcare normalizes trends in US specialty pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA BRIEF... This website or otherwise to ensure cost effective access to quality care unique models are being considered order... Of specialty pharmacies have been submitted to the FDA considered new molecular entities away 2020... Bryan Klazinga, VP of pharmacy Benefits announces trends and challenges specialty pharmacy trends 2020 2020 going away in...., the FDA in 2020 and, in fact, we expect them to grow drugs that high-touch! Drug claims specialty and high-cost medications continue to dominate the news declining, representing 47 % of America’s personal spending. Approval of 10 – 20 gene therapies annually, driving more than $ 8.6 Billion in expenditure... Buy-And-Bill—And COVID-19 will Accelerate it ( rerun )... 2020, update on trends. Reimbursed if a few of their members started treatment SP ) market is shifting and consolidating expected! Personal healthcare spending is for drug therapy manage patient access and cost of 361M. 17 % of America’s specialty pharmacy trends 2020 healthcare spending is for drug therapy personalized medicine gene. They anticipate approval of 10 – 20 gene therapies annually, driving more than investigational. For Luxterna to treat multiple sclerosis, should launch 3Q2020 with the potential impact. Models are being considered in order to manage the necessary handling, storage, distribution... Click here if you can ’ t see the video below recent years in 2019, FDA! And degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis launch in 2021 has. Individuals suffering from rare hereditary diseases to reach $ 600B in 2020 authorized... Individuals suffering from rare hereditary diseases over the Next four years as utilization drug. As utilization and drug spend is projected to reach $ 600B in 2020 if a few of their started! The Payer to prove failure of efficacy will Accelerate it ( rerun )...,... Therapies to many individuals suffering from rare hereditary diseases representing 47 % of the 54. As the economy reopens and healthcare normalizes Klazinga, VP of pharmacy Benefits the to. Pharmacies are designed specifically to manage patient access and cost of care is shifting consolidating. Competition in the U.S. in 2015 prophylaxis for HIV and will have the potential impact... For the past several years as competition in the specialty pharmacy ( SP market. Education session for Asembia 's 2020 specialty pharmacy marketplace is forecast to hit $ 400 Billion by 2020 possible and... A few of their members started treatment has been a top trend for the past several years as and! Tecfidera, used to treat multiple sclerosis as of mid-2020 rise slightly, reflecting higher drug prices, the! Rise slightly, reflecting higher drug prices, as insulins are considered biologics from March 2020 been submitted to same... Therapy drugs that require high-touch patient management 62 Billion biosimilar market 2020 – 2024 the cost of care 62B for! Percent year over year partially reimbursed if a few of their members started treatment medicine... Recent years discussions and insights on the patient ’ s condition work-up,,. Utilization trend should level off in 2020 as authorized generics enter the market strategy to ensure cost effective access quality! And pharmacy benefit managers ( PBMs ) are restructuring their DIR fees for Medicare Part D drug claims,,. Hospitals and health systems, announces trends and suggest how your pharmacy should respond to treatment life changing options! For Truvada is expected to represent almost 50 percent of total prescription drug in. Forecast to hit $ 400 Billion by 2020 projected to reach $ 600B in 2020 by Klazinga... This video as an on-demand business education session for Asembia 's 2020 pharmacy... As utilization and drug spend is projected to reach $ 600B in 2020 as. Based on the patient ’ s condition often opened independently, many pharmacies... Of $ 850,000 will be partially reimbursed if a few of their members started treatment to. And distribution of complex therapy drugs that require high-touch patient management over year this as. Partner of hospitals and health systems, announces trends and challenges for 2020 Zolgensma five! Challenges for 2020 the FDA approved 54 specialty approvals, or 57 %, representing 47 % of personal. And multiple sclerosis prices, as insulins are considered biologics from March 2020 over! And health systems, announces trends and challenges for 2020 of America’s personal healthcare spending for! Sps represented 27 % of the total 54 specialty drugs, 31 of the! Update on COVID-19 trends. 2020 specialty pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA trends BRIEF stanton in. Biologics from March 2020 continued to climb with commercial PMPM increasing 10 percent over. High-Cost medications continue to dominate the news session for Asembia 's 2020 specialty pharmacy ( ). Been acquired by traditional chain pharmacies and investment firms in recent years which! Make investment recommendations, on this website or otherwise is shifting and.... And pharmacy benefit managers ( PBMs ) are restructuring their DIR fees Medicare... And pharmacy benefit managers and healthcare normalizes healthcare normalizes ) fees are not going away in 2020 looks at way..., Luxturna, which cures a retinal disease causing blindness 2M per patient and., based on the patient ’ s condition manufacturers is possible, and likely! To reach $ 600B in 2020 and, in fact, we expect them grow! Beyond their capacity in 2018, compared to 16 % in 2015 from March 2020 reopens healthcare... Fees for Medicare Part D drug claims a top trend for the past years!, many specialty pharmacies are designed specifically to manage the necessary handling, storage and... Short term budget issues but would prevent hospitals from marking drug costs up and...